Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06363630 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT06363630 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 35 participants.
The verdict
NCT06363630, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the drug-drug interaction (DDI) potential of coadministration of itraconazole or rifampin on the single dose drug levels of golcadomide.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG Golcadomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-04-23 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06363630
The ClinicalTrials.gov registry entry for NCT06363630 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT06363630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06363630 about?
NCT06363630 is a clinical study titled "A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants". The purpose of this study is to evaluate the drug-drug interaction (DDI) potential of coadministration of itraconazole or rifampin on the single dose drug levels of golcadomide.
What is the current status of trial NCT06363630?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2024-04-23. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT06363630?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), Golcadomide (DRUG).
Who is sponsoring clinical trial NCT06363630?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.